50
Participants
Start Date
April 1, 2000
Primary Completion Date
September 1, 2005
Study Completion Date
December 16, 2014
carmustine
300 mg/m2 IV on Day -6
cytarabine
100 mg/m2 BID on Days -5 through -2
etoposide
100 mg/m2 BID on Days -5 through -2
melphalan
140 mg/m2 IV on Day -1
peripheral blood stem cell transplantation
Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
tositumomab and iodine I 131 tositumomab
"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
UNMC Eppley Cancer Center at University of Nebraska Medical Center, Omaha
University of Nebraska
OTHER